<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4315">
  <stage>Registered</stage>
  <submitdate>23/12/2013</submitdate>
  <approvaldate>23/12/2013</approvaldate>
  <nctid>NCT02022930</nctid>
  <trial_identification>
    <studytitle>Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis</studytitle>
    <scientifictitle>A Multi-center, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Hydros and Hydros-TA Joint Therapies for Management of Pain Associated With Osteoarthritis in the Knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>COR1.1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the Knee</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Hydros
Treatment: devices - Hydros-TA
Treatment: drugs - Triamcinolone Acetonide

Experimental: Hydros - Hydros Joint Therapy

Experimental: Hydros-TA - Hydros-TA Joint Therapy

Active Comparator: Triamcinolone acetonide - Triamcinolone acetonide


Treatment: devices: Hydros


Treatment: devices: Hydros-TA


Treatment: drugs: Triamcinolone Acetonide


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in the WOMAC A subscale score for the treatment knee.</outcome>
      <timepoint>2 weeks and 26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Strict positive responders to treatment for symptomatic primary osteoarthritis of the knee</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have radiographic evidence within the prior 6 months, as shown in the radiology
             reports, of OA grade 2 or 3 using Kellgren-Lawrence Grading for OA.

          -  Symptoms in the index knee for at least 12 months.

          -  Fully ambulatory Subject (ability to perform a 15 meters walk test).

          -  Male and female Subjects 40 through 85 years of age.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  BMI &gt;40 kg

          -  Secondary OA (acute knee injury, rheumatoid arthritis, gout, history of joint
             infection, osteonecrosis, chronic fibromyalgia) or other chronic autoimmune disease.

          -  Intra articular steroid therapy in last 3 months

          -  Intra articular viscosupplementation in last 6 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>510</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital> - St.Leonards</hospital>
    <postcode> - St.Leonards</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Oshawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands Antilles</country>
      <state>Curacao</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Carbylan Therapeutics, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and efficacy of Hydros-TA Joint Therapy
      for relief of pain due to OA of the knee. Hydros-TA is designed to provide fast acting and
      long lasting pain relief for up to six months with a single IA injection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02022930</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>